Advanced imaging technology detects undiagnosed metastases in high-risk prostate cancer

A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than previously thought.

COMPASS Pathways Projects 2027 Commercialization Timeline For Psilocybin Therapy

With timelines for the submission of approval for MDMA-assisted therapy becoming more clear, COMPASS Pathways (NASDAQ:CMPS) has provided their own estimation on when psilocybin-assisted therapy

July 6, 2023

Opinion | It’s Match Week, but That Won’t Fix the Physician Shortage

Kumar is a medical student. Leitman is a professor of surgery and medical education, and a dean for graduate medical education. On March 15, tens

March 13, 2024

MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction – Biotech Investments

EQS-News: MorphoSys AG / Key word(s): Study results MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and

November 21, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.